🍽️ venlafaxine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antidepressant Effects: Venlafaxine is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters involved in regulating mood. By enhancing neurotransmitter activity, venlafaxine alleviates symptoms of depression and improves mood in individuals with MDD.

  2. Anxiolytic Effects: In addition to treating depression, venlafaxine is also effective in managing various anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. Its mechanism of action in anxiety disorders is believed to involve modulation of serotonin and norepinephrine levels in key brain regions associated with anxiety regulation.

  3. Panic Disorder: Venlafaxine is FDA-approved for the treatment of panic disorder with or without agoraphobia. It helps reduce the frequency and severity of panic attacks and associated symptoms, such as palpitations, sweating, trembling, and feelings of impending doom.

  4. Generalized Anxiety Disorder (GAD): Venlafaxine is indicated for the treatment of generalized anxiety disorder characterized by excessive worry and anxiety about various aspects of life. It helps alleviate symptoms such as persistent nervousness, restlessness, tension, and irritability.

  5. Social Anxiety Disorder (Social Phobia): Venlafaxine may be prescribed off-label for the treatment of social anxiety disorder, a condition characterized by intense fear or anxiety in social situations. It can help reduce social anxiety symptoms and improve social functioning.

  6. Dosage Forms: Venlafaxine is available in various dosage forms, including immediate-release tablets, extended-release capsules, and extended-release tablets. The extended-release formulations are designed to provide a sustained release of the medication over time, allowing for once-daily dosing and improved tolerability.

  7. Adverse Effects: Common side effects of venlafaxine may include nausea, headache, dizziness, insomnia, somnolence (drowsiness), dry mouth, constipation, loss of appetite, sweating, and sexual dysfunction. These side effects are usually mild to moderate in intensity and often transient, but they may necessitate dose adjustments or discontinuation of therapy in some cases.

  8. Withdrawal Symptoms: Abrupt discontinuation of venlafaxine may lead to withdrawal symptoms, commonly referred to as discontinuation syndrome. Symptoms may include flu-like symptoms, dizziness, nausea, headache, irritability, insomnia, electric shock sensations (paresthesia), and mood swings. It is important to gradually taper the dose of venlafaxine under medical supervision to minimize the risk of withdrawal symptoms.

  9. Serotonin Syndrome: Like other antidepressants, venlafaxine carries a risk of serotonin syndrome, a potentially life-threatening condition characterized by excessive serotonin activity in the brain. Serotonin syndrome may occur when venlafaxine is used concomitantly with other serotonergic medications or substances, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans, and certain herbal supplements.

  10. Contraindications: Venlafaxine is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should not be used concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to the risk of serotonin syndrome. Venlafaxine should be used with caution in patients with certain medical conditions, such as cardiovascular disease, hepatic impairment, renal impairment, and seizure disorders.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of venlafaxine,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by venlafaxine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Lachnospira genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Odoribacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Roseburia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Clostridium genus Decreases 👪 Source Study Pathogen
Streptococcus genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Lachnospira eligens species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Roseburia hominis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Dorea formicigenerans species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Ruminococcus bromii species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Clostridioides difficile species Decreases 📓 Source Study Colitis
[Ruminococcus] torques species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bifidobacterium longum species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Streptococcus parasanguinis species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of venlafaxine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 -0.3
ADHD 2.8 0.3 8.33
Age-Related Macular Degeneration and Glaucoma 0.4 0.1 3
Allergic Rhinitis (Hay Fever) 1.1 1.3 -0.18
Allergies 3.8 2.1 0.81
Allergy to milk products 1 0.7 0.43
Alopecia (Hair Loss) 1 1
Alzheimer's disease 3 3.8 -0.27
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.4 1.6 1.13
Ankylosing spondylitis 2.7 1.4 0.93
Anorexia Nervosa 0.1 1.6 -15
Antiphospholipid syndrome (APS) 0.9 0.9
Asthma 0.9 1.5 -0.67
Atherosclerosis 1 1.6 -0.6
Atrial fibrillation 2.4 0.8 2
Autism 6.1 6.6 -0.08
Barrett esophagus cancer 0.7 0.1 6
benign prostatic hyperplasia 0.3 0.3
Biofilm 1.6 1.6
Bipolar Disorder 0.8 1.1 -0.38
Brain Trauma 0.6 0.4 0.5
Cancer (General) 0.3 1.9 -5.33
Carcinoma 2.7 2.1 0.29
Celiac Disease 1.7 3.1 -0.82
Cerebral Palsy 1.3 0.9 0.44
Chronic Fatigue Syndrome 4.6 3.8 0.21
Chronic Kidney Disease 1.6 1.2 0.33
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 1.1 0.6 0.83
Chronic Urticaria (Hives) 1.5 1.1 0.36
Coagulation / Micro clot triggering bacteria 1.1 0.9 0.22
Colorectal Cancer 3.3 0.8 3.12
Constipation 0.9 0.6 0.5
Coronary artery disease 1.1 0.9 0.22
COVID-19 9 9.2 -0.02
Crohn's Disease 5.8 4.6 0.26
cystic fibrosis 0.9 0.6 0.5
deep vein thrombosis 0.9 0.5 0.8
Depression 6.2 5.7 0.09
Dermatomyositis 0.1 0.3 -2
Eczema 1.2 1 0.2
Endometriosis 2.1 1.4 0.5
Eosinophilic Esophagitis 0.2 0.5 -1.5
Epilepsy 2.5 2.4 0.04
Fibromyalgia 1.9 0.5 2.8
Functional constipation / chronic idiopathic constipation 3.2 1.7 0.88
gallstone disease (gsd) 1.8 0.7 1.57
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.1 0.9 0.22
Generalized anxiety disorder 1.9 0.7 1.71
giant cell arteritis 0.1 -0.1
Glioblastoma 0.1 -0.1
Graves' disease 0.9 1.2 -0.33
Halitosis 0.8 0.1 7
Hashimoto's thyroiditis 2 0.4 4
Hidradenitis Suppurativa 0.3 0.5 -0.67
High Histamine/low DAO 1.1 0.4 1.75
hypercholesterolemia (High Cholesterol) 0.4 0.8 -1
hyperglycemia 0.5 2.1 -3.2
Hyperlipidemia (High Blood Fats) 1 0.4 1.5
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 1.9 3.8 -1
Hypothyroidism 1 -1
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 1.8 -1.8
Inflammatory Bowel Disease 3.5 5.1 -0.46
Insomnia 0.6 0.7 -0.17
Intelligence 0.1 0.1
Intracranial aneurysms 0.9 0.4 1.25
Irritable Bowel Syndrome 3.3 2.7 0.22
Liver Cirrhosis 3.4 2.1 0.62
Long COVID 5.3 6.7 -0.26
Low bone mineral density 0.6 -0.6
Lung Cancer 0.6 1.6 -1.67
Mast Cell Issues / mastitis 0.4 0.4 0
ME/CFS with IBS 0.2 1.7 -7.5
ME/CFS without IBS 1.5 1.1 0.36
Menopause 1.4 1.4
Metabolic Syndrome 6 5.6 0.07
Mood Disorders 8.6 6 0.43
multiple chemical sensitivity [MCS] 1.1 0.4 1.75
Multiple Sclerosis 4.1 2.5 0.64
Multiple system atrophy (MSA) 1.9 0.9 1.11
neuropathic pain 1.6 -1.6
Neuropathy (all types) 0.9 0.3 2
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.5 4.7 -2.13
NonCeliac Gluten Sensitivity 2.1 0.4 4.25
Obesity 6.5 3.9 0.67
obsessive-compulsive disorder 4.3 3.1 0.39
Osteoarthritis 1.6 0.2 7
Osteoporosis 1.5 1.3 0.15
pancreatic cancer 0.4 0.4
Parkinson's Disease 5.7 4.5 0.27
Polycystic ovary syndrome 1.3 1.7 -0.31
Postural orthostatic tachycardia syndrome 0.1 0.3 -2
Premenstrual dysphoric disorder 1 0.1 9
primary biliary cholangitis 0.2 0.4 -1
Psoriasis 4 1.3 2.08
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.9 2.7 0.81
Rosacea 0.8 0.3 1.67
Schizophrenia 5.2 1.1 3.73
scoliosis 0.9 -0.9
Sjögren syndrome 2.6 2.2 0.18
Sleep Apnea 1.1 1 0.1
Slow gastric motility / Gastroparesis 1.4 0.3 3.67
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.2 3.5
Stress / posttraumatic stress disorder 2.3 2.3 0
Systemic Lupus Erythematosus 3.2 1.8 0.78
Tic Disorder 0.6 0.8 -0.33
Tourette syndrome 0.4 0.2 1
Type 1 Diabetes 2.2 1.7 0.29
Type 2 Diabetes 6 4.2 0.43
Ulcerative colitis 2.3 2.7 -0.17
Unhealthy Ageing 3.1 1.5 1.07
Vitiligo 1.3 0.9 0.44

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]